KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Change in Cash: 2019-2025

Historic Change in Cash for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $307.0 million.

  • Royalty Pharma's Change in Cash rose 137.69% to $307.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year decrease of 181.65%. This contributed to the annual value of $452.0 million for FY2024, which is 136.64% up from last year.
  • As of Q3 2025, Royalty Pharma's Change in Cash stood at $307.0 million, which was up 167.36% from -$455.8 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Change in Cash peaked at $921.6 million during Q2 2024, and registered a low of -$1.2 billion during Q3 2023.
  • Moreover, its 3-year median value for Change in Cash was $158.7 million (2025), whereas its average is -$70.2 million.
  • Within the past 5 years, the most significant YoY rise in Royalty Pharma's Change in Cash was 376.84% (2022), while the steepest drop was 269.53% (2022).
  • Royalty Pharma's Change in Cash (Quarterly) stood at -$259.8 million in 2021, then skyrocketed by 376.84% to $719.1 million in 2022, then crashed by 163.89% to -$459.4 million in 2023, then soared by 95.42% to -$21.0 million in 2024, then spiked by 137.69% to $307.0 million in 2025.
  • Its Change in Cash stands at $307.0 million for Q3 2025, versus -$455.8 million for Q2 2025 and $158.7 million for Q1 2025.